Transitional cell cancer of the renal pelvis and ureter is a rare type of cancer affecting the upper urinary tract, where cells lining the kidney’s central area and the tubes connecting it to the bladder begin to grow uncontrollably. Though uncommon, this cancer is highly treatable when caught early, and modern medicine offers a growing range of treatment options, from traditional surgery to emerging therapies being tested in clinical trials.

How Treatment Decisions Are Made

When a person receives a diagnosis of transitional cell cancer of the renal pelvis or ureter, treatment planning begins immediately. The main goals of treatment are to remove or destroy cancer cells, prevent the disease from spreading, and help patients maintain the best possible quality of life. The approach chosen depends heavily on how deeply the cancer has grown into the urinary tract walls and whether it has spread to nearby tissues or distant organs.^[1]

The stage and grade of the cancer guide doctors in selecting treatments. Superficial cancers that remain on the inner lining of the renal pelvis or ureter respond very differently than deeply invasive tumors that have penetrated through multiple layers of tissue. These deeper tumors require more aggressive treatment strategies.^[2]

Treatment also depends on individual patient characteristics. A person’s overall health, kidney function, age, and personal preferences all play important roles. For example, someone with only one functioning kidney might need a different approach than someone with two healthy kidneys. Medical teams also consider whether cancer has appeared in both sides of the urinary tract or if there is a history of bladder cancer, which is common in these patients.^[1]

Medical societies and expert panels have established standard treatment recommendations based on decades of research and patient outcomes. At the same time, researchers continue to explore new therapies through clinical trials, offering hope that future treatments may be even more effective with fewer side effects.^[1]

Standard Treatment Approaches

Surgery as the Main Treatment

Surgery remains the cornerstone of treatment for transitional cell cancer of the renal pelvis and ureter. The gold standard surgical approach is called radical nephroureterectomy, which involves removing the entire kidney, the complete ureter, and a small section of the bladder where the ureter connects. This extensive removal is necessary because cancer cells can spread along the length of the ureter, and leaving any portion behind carries a high risk that cancer will return in that remaining tissue.^[2]

The reason for such thorough removal becomes clear when we look at the numbers. Studies have shown that if the ureteral stump is left behind, cancer recurs in that area in 30% to 75% of cases. This makes complete removal essential for giving patients the best chance of cure.^[13]

Surgeons can perform nephroureterectomy through two main techniques. Open surgery involves making a large incision along the side and abdomen to remove the organs and surrounding tissue. Laparoscopic surgery uses several small incisions through which a camera and specialized instruments are inserted to complete the same removal. Laparoscopic approaches generally lead to shorter hospital stays and faster recovery times, though both methods are effective.^[12]

When cancer is detected early and remains superficial—meaning it hasn’t grown deep into the tissue walls—more than 90% of patients can be cured. However, if the tumor has invaded deeply into the wall of the renal pelvis or ureter but hasn’t spread beyond, the cure rate drops to 10% to 15%. This dramatic difference underscores why early detection matters so much.^[2]

Kidney-Sparing Surgery

Not everyone needs to lose an entire kidney. In carefully selected patients with small, low-grade tumors, doctors may recommend kidney-sparing procedures. One option is segmental resection of the ureter, where surgeons remove only the affected portion of the ureter along with a margin of healthy tissue above the tumor, then reconnect the ureter to the bladder. This approach works best for small tumors in the lower part of the ureter closest to the bladder.^[12]

Kidney-sparing surgery is particularly important for people who have only one kidney, those whose other kidney doesn’t function well, or patients with cancer affecting both sides of the urinary tract. Preserving kidney function helps avoid the need for dialysis and maintains better overall health.^[14]

Recent studies have shown that in patients with low-risk tumors—those that are small, single, low-grade, and without signs of invasion—kidney-sparing management can preserve kidney function in about 81% of cases while maintaining excellent cancer-specific survival rates of 94.7%. These outcomes have led experts to increasingly recommend this conservative approach for appropriate patients.^[14]

Endoscopic Treatment

Endoscopic surgery represents the most minimally invasive option available. During this procedure, surgeons pass a thin tube with a camera through either the urethra and bladder (ureteroscopy) or through a small incision in the side directly into the kidney (percutaneous endoscopy). Specialized cutting tools or lasers passed through the endoscope allow the surgeon to remove or destroy the tumor.^[12]

This approach works best for small, low-grade tumors that haven’t invaded deeply. European medical guidelines specifically recommend endoscopic treatment as a primary option when the tumor is single, measures less than 2 centimeters, appears low-grade on biopsy and urine tests, and shows no signs of deep invasion on imaging scans.^[14]

The major advantage of endoscopic treatment is that it preserves the kidney entirely. However, it requires rigorous follow-up because tumors can recur. Patients typically undergo a second endoscopic examination within eight weeks to ensure all cancer has been removed. Despite this need for close monitoring, endoscopic management offers excellent results for properly selected patients.^[14]

Chemotherapy

Chemotherapy uses powerful drugs that travel through the bloodstream to kill cancer cells throughout the body. For transitional cell cancer of the renal pelvis and ureter, chemotherapy is most often given after surgery as adjuvant therapy. This means it’s used to eliminate any cancer cells that might have spread beyond the surgical area but are too small to detect on scans.^[12]

Chemotherapy is particularly recommended for patients whose cancer had spread to nearby lymph nodes or had grown deeply through the urinary tract wall at the time of surgery. It’s also used when cancer has already spread to distant organs. Because these upper tract cancers come from the same type of cells as bladder cancer, doctors use similar chemotherapy drugs.^[1]

The timing of chemotherapy matters. Some doctors prefer to give chemotherapy before surgery, called neoadjuvant chemotherapy. The advantage of this approach is that patients still have both kidneys functioning, which means they can tolerate the full doses of cisplatin-based chemotherapy regimens. These drugs can be hard on the kidneys, and having only one kidney after surgery may limit treatment options.^[14]

Common side effects of chemotherapy include nausea, fatigue, increased risk of infection due to low blood cell counts, hair loss, and changes in appetite. The specific side effects depend on which drugs are used. Medical teams carefully monitor patients receiving chemotherapy and provide supportive medications to manage side effects.^[12]

Radiation Therapy

Radiation therapy uses high-energy beams to destroy cancer cells. Its role in treating transitional cell cancer of the renal pelvis and ureter is less well-defined than in some other cancers. Some studies suggest that radiation given after surgery (adjuvant radiation) may help improve local control of high-grade disease, meaning it reduces the chance of cancer returning in the area where it was removed.^[14]

Radiation is sometimes recommended when surgery isn’t possible due to a patient’s overall health condition, or when cancer cannot be completely removed surgically. It may also be used to relieve symptoms such as pain or bleeding in patients with advanced disease.^[12]

Topical Immunotherapy

Topical immunotherapy involves placing medication directly into the renal pelvis or ureter to stimulate the immune system to attack cancer cells. This approach is similar to treatments used for bladder cancer. The medication is delivered through a catheter and allowed to remain in contact with the urinary tract lining for a period of time before being drained.^[14]

This treatment option is typically considered for patients with carcinoma in situ (a very early stage where cancer cells are present only on the surface) or after endoscopic removal of small tumors to reduce the risk of recurrence. While topical therapy can be effective, it generally has higher recurrence rates compared to surgical removal of the entire kidney and ureter.^[13]

Innovative Therapies in Clinical Trials

Clinical trials are research studies that test new ways to prevent, detect, or treat disease. For transitional cell cancer of the renal pelvis and ureter, several promising therapies are currently being investigated that may change how this cancer is treated in the future.

Understanding Clinical Trial Phases

Clinical trials progress through three main phases. Phase I trials focus primarily on safety, determining what doses of a new treatment can be given safely and identifying side effects. Phase II trials test whether the treatment works against the specific cancer and continue to monitor safety. Phase III trials compare the new treatment directly against current standard treatments to see if it works better, has fewer side effects, or offers other advantages.^[1]

Immune Checkpoint Inhibitors

One of the most exciting developments in cancer treatment involves immune checkpoint inhibitors, drugs that help the body’s immune system recognize and attack cancer cells. These medications work by blocking proteins that prevent immune cells from attacking cancer. They’re called checkpoint inhibitors because they release the “brakes” on the immune system.^[1]

Several immune checkpoint inhibitors are being tested in clinical trials for upper urinary tract cancers. These include drugs known as PD-1/PD-L1 inhibitors, which target specific proteins on cancer cells or immune cells. Because these cancers are closely related to bladder cancer, researchers are adapting successful bladder cancer immunotherapies for upper tract disease.^[14]

These drugs are given through intravenous infusion, typically every few weeks. Unlike traditional chemotherapy, they don’t directly kill cancer cells. Instead, they empower the patient’s own immune system to do the work. Side effects differ from chemotherapy and can include fatigue, skin rash, inflammation of various organs, and autoimmune reactions where the immune system attacks normal tissues.^[1]

Targeted Therapies

Targeted therapy refers to drugs designed to attack specific molecular abnormalities in cancer cells. Scientists have discovered that some transitional cell cancers have mutations or changes in specific genes or proteins that drive cancer growth. Drugs that target these specific changes can potentially stop cancer growth while causing less harm to normal cells than traditional chemotherapy.^[1]

FGFR inhibitors are one type of targeted therapy being studied. FGFR stands for fibroblast growth factor receptor, a protein that helps cells grow and divide. Some transitional cell cancers have mutations in FGFR genes, and drugs that block these proteins have shown promise in early trials. These medications are taken as pills and work specifically against cancer cells with FGFR mutations.^[14]

Another targeted approach involves anti-Nectin-4 monoclonal antibodies. Nectin-4 is a protein found on the surface of many urothelial cancer cells. These antibodies attach to Nectin-4 and deliver chemotherapy directly to cancer cells, a strategy called an antibody-drug conjugate. This targeted delivery system aims to maximize the cancer-killing effect while minimizing damage to healthy tissues.^[14]

Combination Approaches

Researchers are increasingly testing combinations of different therapies. For example, combining immune checkpoint inhibitors with chemotherapy may work better than either treatment alone. The chemotherapy may make cancer cells more visible to the immune system, while the immunotherapy helps the immune system attack more effectively. Other studies are examining combinations of different immunotherapy drugs or immunotherapy with targeted therapies.^[1]

Who Can Join Clinical Trials

Clinical trials have specific eligibility criteria that determine who can participate. These criteria typically include the stage and grade of cancer, previous treatments received, overall health status, and kidney function. Some trials are looking for patients who haven’t had treatment yet, while others focus on people whose cancer has returned or spread despite standard treatments.^[1]

Trials are conducted at major cancer centers in many locations, including the United States, Europe, and other regions. Participating in a clinical trial gives patients access to potentially effective new treatments before they become widely available, along with close monitoring by expert medical teams.

Most common treatment methods

• Surgery
  • Radical nephroureterectomy involves removing the entire kidney, complete ureter, and a section of bladder to prevent cancer recurrence in remaining tissue
  • Segmental resection of the ureter removes only the affected portion for small tumors in the lower ureter, preserving kidney function
  • Endoscopic surgery uses a thin tube with camera and tools to remove or destroy small, low-grade tumors through minimally invasive approaches
  • Laparoscopic techniques allow complete organ removal through small incisions with faster recovery than traditional open surgery
• Chemotherapy
  • Systemic chemotherapy uses drugs that travel through the bloodstream to kill cancer cells, often given after surgery to eliminate microscopic disease
  • Neoadjuvant chemotherapy given before surgery takes advantage of full kidney function to deliver optimal drug doses
  • Cisplatin-based regimens are commonly used, similar to protocols for bladder cancer
  • Adjuvant chemotherapy is recommended when cancer has spread to lymph nodes or grown deeply through tissue walls
• Immunotherapy
  • Topical immunotherapy delivers medication directly into the renal pelvis or ureter to stimulate local immune response against cancer cells
  • PD-1/PD-L1 checkpoint inhibitors release immune system brakes, helping the body recognize and attack cancer cells
  • Systemic immunotherapy is being tested in clinical trials for advanced or recurrent disease
• Radiation Therapy
  • External beam radiation uses high-energy beams to destroy cancer cells in specific areas
  • Adjuvant radiation after surgery may improve local control for high-grade tumors
  • Palliative radiation can relieve symptoms like pain or bleeding in advanced disease
• Targeted Therapy
  • FGFR inhibitors block specific proteins in cancer cells with FGFR gene mutations
  • Anti-Nectin-4 antibody-drug conjugates deliver chemotherapy directly to cancer cells expressing Nectin-4 protein
  • These treatments are currently being studied in clinical trials for metastatic or recurrent disease